Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility

被引:43
作者
Jones, RN [1 ]
机构
[1] Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, Iowa City, IA 52242 USA
关键词
D O I
10.1093/jac/46.suppl_2.1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Communicating information from antimicrobial resistance surveillance study data to microbiologists and physicians can be challenging. Large amounts of data, commonly reaching millions of MICs or zone diameter endpoints, must be analysed and condensed to easily-read tables or figures, Furthermore, data must not be prejudged relative to susceptibility categories, because of the diverse nature of interpretive criteria available internationally. An attempt must be made to present results of all surveillance studies in a mode that can be reinterpreted for immediate use in different geographical areas, or used to compare future data with relative ease and high accuracy. Such data displays require peer-reviewed journals to permit greater numbers of more complex tables to present results, The Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) study is a year-on-year global surveillance programme in medical centres where meropenem is available for use. We have developed a presentation strategy that expands the long-term clinical value of MYSTIC results. In addition to statistical parameters, tables of cumulative percentages or numbers of strains inhibited at each tested antimicrobial concentration will be presented, Alternative figures (Finland-o-grams) could also be used, but these generally lack precise extractable rates and require more journal space, Regardless of study design, promotion of this presentation philosophy enhances any surveillance study's value to each reader or user and facilitates application to locally appropriate interpretations. The widespread use of these analysis and presentation principles as benchmarks by various resistance studies and networks is strongly encouraged, particularly by investigations across international boundaries.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 51 条
  • [1] *1997 AM SOC CLIN, 1999, DIAGN MICROBIOL INFE, V35, P143
  • [2] [Anonymous], ANTIMICROB AGENTS S
  • [3] [Anonymous], M100S10 NCCLS
  • [4] Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA
    Ballow, CH
    Jones, RN
    Johnson, DM
    Deinhart, JA
    Schentag, JJ
    Tritsch, M
    Ellis, S
    Burger, J
    Cole, E
    Venezia, R
    George, M
    Wolf, D
    Slifkin, M
    DePalma, J
    Rudrik, J
    Sullivan, K
    Lewis, G
    Dooley, G
    Sawicki, R
    Desiderio, D
    Louma, R
    Motyl, M
    Ruffin, L
    Torresan, J
    Dunaway, G
    Keck, G
    Truitt, L
    Brecher, S
    VanEnk, R
    Whelen, C
    Fader, R
    Whisler, G
    Jenkins, S
    Thacker, D
    DAmato, R
    Buck, R
    Buescher, S
    Lambert, K
    Tristram, D
    Kehl, S
    Lawson, C
    Washington, J
    Robertson, K
    Beall, A
    Padgett, L
    Rahman, L
    Riddle, G
    DellaLatta, P
    Marcon, M
    Northern, I
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 29 (03) : 173 - 186
  • [5] EUROPEAN STANDARDS FOR ANTIBIOTIC SUSCEPTIBILITY TESTING - TOWARDS A THEORETICAL CONSENSUS
    BAQUERO, F
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1990, 9 (07) : 492 - 495
  • [6] COMPARISON OF INVITRO ACTIVITY OF CEPHALEXIN, CEPHRADINE, AND CEFACLOR
    BILL, NJ
    WASHINGTON, JA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1977, 11 (03) : 470 - 474
  • [7] BOOGAERTS MA, 1995, J ANTIMICROB CHEMOTH, V36, P185
  • [8] Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein
    Bradford, PA
    Urban, C
    Mariano, N
    Projan, SJ
    Rahal, JJ
    Bush, K
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) : 563 - 569
  • [9] CLINICAL-EVALUATION OF MEROPENEM VERSUS CEFTAZIDIME FOR THE TREATMENT OF PSEUDOMONAS SPP INFECTIONS IN CYSTIC-FIBROSIS PATIENTS
    BYRNE, S
    MADDISON, J
    CONNOR, P
    DOUGHTY, I
    DODD, M
    JENNEY, M
    WEBB, AK
    DAVID, TJ
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 : 135 - 143
  • [10] Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients
    Colardyn, F
    Faulkner, KL
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 38 (03) : 523 - 537